Germany's adult-use framework, one year in: what actually changed

Germany's reform took effect in April 2024 and the operational changes are now measurable. The biggest one — and the one that has surprised even sympathetic observers — is the scale of the medical program expansion that followed.

The medical surge

The 2024 reform removed cannabis from Germany's Narcotics Act for medical prescriptions, eliminating one of the most significant administrative frictions in the program. Patient counts more than doubled in the first year, telemedicine prescribing platforms scaled aggressively, and pharmacy distribution volumes broke records.

The cultivation association story

The Anbauvereinigungen — non-commercial cultivation associations — were the most distinctive design element of the German law. In practice, they remain operationally underutilized. Registration friction, geographic constraints, and the comparatively low cap on output per member have kept them from becoming a meaningful share of national consumption.

The export effect

From a market-structure standpoint, the German medical demand expansion is the most consequential cannabis trade story of the last two years. Imported flower volumes from Canada, Portugal, and Australia hit record levels. EU-GMP certified production capacity is now the binding constraint, and operators with that capacity are commanding premium pricing.

What's still uncertain

The political question — whether Germany expands the framework to a commercial retail program or holds the current hybrid in place — remains unresolved. The coalition arithmetic in Berlin has shifted enough that no one we've spoken to is willing to forecast a near-term answer.